NR1H3 and acute myeloid leukemia: One of the effective compounds, butein (45), increased CYP7A1 luciferase activity in AML 12 cells via activating LXRα dependently and upregulating the transcriptional expression level of LXRα, which was borne out using the knockdown of LXRα (Jeong et al., 2015).